Sheliagin diuretic therapy of the chronic heart failure

The Chronic Heart Failure (CHF) - very widespread disease as many cardiovascular diseases in the outcome cause a heart failure. CHF involves permanent disability and hospitalization of patients therefore treatment of CHF is topical issue. The most widespread manifestation of CHF is the edematous syndrome which emergence can threaten with serious complications and hypostasis of internals or the general swelling. Therefore diuretic therapy, more precisely, the choice of the safest and efficient medicines remains an important question in treatment of CHF. Most often application of diuretics causes the pointed natriuresis or a phenomenon of "ricochet" which is characterized by sharp increase in concentration of sodium in a distal canaliculus of kidneys that leads to sharp defeat of glomerulus a large amount of sodium, especially when using high doses of medicines. Partly, these processes can cause a resistance of edematous syndrom to diuretic therapy. A problem is the choice of the drug, not possessing phenomenon of "ricochet" but having high performance and a possibility of maintaining of a constant concentration of medicine in blood without application of "shock doses" which consequence deterioration in function of kidneys, decrease in Glomerular Filtration Rate (GFR) and the expressed side effects is (loss of electrolytes - a hypopotassemia). This literature review takes up the common questions of diuretic therapy at CHF, and also researches of torasemid, including with sustained-release which cause not only decrease of symptoms of CHF, but also are capable to influence the forecast of a disease.